Buffer Stock Blending (BSB) System: Published papers describing the project, drivers, concept and economic model

Buffers are critical inputs into all downstream processing steps associated with the manufacture of therapeutic proteins. The large volumes of buffer required present ongoing logistical challenges and account for a significant portion of a facility’s footprint, labor requirements and equipment costs.

The first edition Biomanufacturing Technology Roadmap identified the improvement of buffer management as a key strategic need for the industry. A collaboration of leading biopharmaceutical companies, engineering firms and suppliers has been working together to develop a design for a Buffer Stock Blending (BSB) System to support the preparation of buffers in-line and on demand from concentrated single-component stock solutions.

Early work on a user requirements specification fueled a desire to prototype the design and the team obtained funding from NIIMBL* to build the skid with vendors IPEC and Pieper Automation.  The functional specification has been signed off and the vendors are moving into the build phase. The team is now preparing for factory acceptance testing, delivery of the Buffer Stock Blending (BSB) System to NIIMBL’s laboratory at the University of Delaware, performance testing and the subsequent release of the design and dataset.

The team has published two white papers. The first, NIIMBL-BioPhorum Buffer Stock Blending System: A More Advanced Concept for Buffer Manufacturing, describes the project and activities up to the award of the contract to IPEC, and explains the industry drivers for change and the team’s approach to buffer preparation. The second paper, An Economic Evaluation of Buffer Preparation Philosophies for the Biopharmaceuticals Industry, is a deep-dive into some of the modeling work done to support the project.  Both available here.

The benefits

To ensure the supply of buffers needed for the manufacture of biotherapeutic products, particularly with an expected increase in upstream productivity, Nathalie Frau (Head Biologics Technology Innovation & Strategy – Downstream Processing at Sanofi) said the industry needs to address the exponential challenges it will face regarding facility footprints, labor requirements, capital costs and logistics.

“The implementation of an automated in-line buffer manufacturing system can significantly reduce capital and operating costs, and minimize the volume of buffers to be prepared per batch, the number of buffers to be prepared and the associated labor,” said Frau. “This technology also offers the possibility to purchase standardized, ready-to-use, concentrated and single-component stock solutions to connect them directly to the buffer manufacturing system.”

For example, the move to single-use bags of less than 2,000L instead of large stainless steel tanks (often more than 12,000L), could create potential savings of more than $20m per facility built. Labor requirements will also be significantly reduced and buffer preparation can be cut from a 3x7-day operation to a 1x5-day operation in each facility.

The technology also has the potential to enable the transition from a predominately stainless steel facility, common today, to a predominately single-use facility of the future, with the potential to deliver a capital reduction of more than $100m for each new facility.

BioPhorum has blazed a trail on this project with some key initiatives:

  • Industry collaboration on requirements (BioPhorum)
  • Using an open architecture – anyone can build and improve it
  • Successful consortium (including NIIMBL) to build and test the prototype.

For more information on the Buffer Preparation project and the NIIMBL-BioPhorum Buffer Stock Blending (BSB) System, please contact Danièle Wiseman on daniele@biophorum.com

* This work was performed under financial assistance award 70NANB17H002 from the US Department of Commerce, National Institute of Standards and Technology.

Attached Files

File
An-economic-evaluation-of-buffer-preparation-philosophies-for-the-biopharmaceutical-industry-December-2019.zip
Preview
  • Version
  • Download 398
  • File Size 9.20 MB
  • File Count 1
  • Create Date 29th November 2019
  • DOI
  • Last Updated

Cell & Gene Therapy

Maximizing the impact of the many advanced therapies under development requires that the industry comes together to improve understanding of how to develop, control and manufacture these life changing therapies.

We connect strategic thinkers in drug development and contract manufacturing organizations with the aim of ensuring harmonization and alignment around issues such as potency assays, phase-appropriate guidance for critical quality attributes, operator safety, regulatory guidelines, and C&GT-specific validation issues, as well as working toward resolving the current challenges to commercializing C&GT products. Discover more and learn about the outputs here.

Development Group

The ever-increasing need to reduce product development lead times and the opportunities to exploit innovative technologies in development are two key industry themes that remain at the forefront of our work. The Phorum successfully connects process development organizations and provides a space where subject matter experts can work on issues such as quality by design and process characterization, cell line technologies, and molecule selection. Read some of the outputs and discover how you could benefit by getting involved.

Drug Substance

Accelerating improvement, exploiting opportunities offered by innovation, and identifying best practice approaches across all aspects of the manufacturing process – these are the essential objectives

Data and digital capabilities are at the core of many of these industry challenges. Work in BioPhorum Drug Substance is informed by BioPhorum Technology Strategy, which has summarized our industry’s market drivers and trends. Capacity, flexibility, sustainability and pace all feature as requirements to succeed in a rapidly changing environment.

Find out more about what our members are currently discussing and learn about some of the successful implementations of our output.

Fill Finish

Quality and demonstrating compliance are two priorities of BioPhorum Fill Finish. Representatives of the world’s top sterile filling operations come together to develop solutions to some of the most intractable technical and regulatory challenges.To address these challenges in drug product aseptic filling (‘fill’) and secondary packaging (‘finish’) operations, our community of industry experts is working relentlessly to continually improve the pharmaceutical quality system (PQS). Together they continue to strive towards developing and implementing safe, predictable, lean, and agile processes in drug product operations. Find out more about the Phorum output here. 

Information Technology

IT and digital advances are crucial in responding to the pharmaceutical industry’s challenges around speed, cost, quality, flexibility, and sustainability. Unlocking and realizing the value in the industry’s IT opportunities is the core mission of the IT Phorum. 

The digital manufacturing facility of the future needs to consider technology advances alongside organizational perspectives while maintaining foundational security requirements. All elements must be considered in the long term to deliver systemic change toward the digital factory vision. Our members collaborate in a format that stimulates and supports industry innovation and implementation. 

Regulatory-CMC

BioPhorum Regulatory CMC is affording professionals the opportunity to shape their own collaboration program focused on challenges and opportunities across strategy, science, operations, submissions and compliance. Following a discovery program of work with Heads of Regulatory CMC, in which we identified some key topics of collaboration, we are giving you the opportunity to participate and help us to shape the final collaboration program. This will focus on, filing and review, interactions with Health Authorities, and harmonization. Our mission is not just to discuss, but to deliver applicable outputs and publications that will have an impact – learn more about how you can get involved.

Supply Chain to Patient

The pharmaceutical outbound supply chain was built on a blockbuster model and doesn’t fit the needs of the changing pipeline and new modalities currently being developed. The geopolitical challenges of recent years have shown that the outbound supply chain needs to evolve to become more agile, and resilient, and address a more expectant end-user bying on patient-centricity. Industry collaboration can accelerate improvements and transform performance in a way not possible when working independently. This Phorum is founded on the belief that learning from each other and challenging current thinking to re-imagine the supply chain can reduce costs and increase efficiency.

Supply Partner

BioPhorum SP members want the inbound supply chain for the biomanufacturing industry to be recognized as one of the best-understood and managed global supply chains. They intend to be not only a trusted advisory group but also the engine that drives change for the industry. Working together, we aim to achieve supply chain transformation that provides:

  • an enhanced robustness and resilience
  • accelerated capability and capacity to effect technology adoption
  • reduced cost of quality, and
  • industry-wide alignment on operational implementation

There’s an extensive list of Phorum successes and tangible benefits that have been delivered to define industry best practise.

Sustainability

The BioPhorum Sustainability program is jointly designed, governed, and delivered by a membership drawn from licence holders, contract manufacturers, major suppliers and niche suppliers. This dynamic partnership means that we can quickly focus on the areas that have the greatest industry impact, and we can leverage learning from each other and other sectors – the chemical industry and the built environment for example.

BioPhorum’s unique ability to build a strong coalition for change for an entire industry is now being applied to the greatest challenge of our generation. Driven by evident industry needs, Phorum members are working to develop agreed industry benchmarks, establish the ROI of sustainability investments and to increase the efficacy of implementation of members’ sustainability strategies.

Technology Strategy

With a mission to define strategies to accelerate technology transformation and support the adoption of innovative technologies, BioPhorum Technology Strategy evolved from BioPhorum Technology Roadmapping, strives to realize the technology roadmap vision 2.0.

This is being achieved through a multi-stakeholder team of member companies with collective capability and influence who are committed to driving forth industry goals associated with: Speed to market, Quality, Value, Agility and On-Demand Supply and Sustainability.

Building on industry feedback to standardize plasmid release specifications

Buffer Stock Blending (BSB) System: Published papers describing the project, drivers, concept and economic model Buffers are critical... read more

How to predict, optimize and analyze high-concentration biologic therapeutic formulations

Buffer Stock Blending (BSB) System: Published papers describing the project, drivers, concept and economic model Buffers are critical... read more

A media fingerprinting toolbox that comes with a host of benefits

Buffer Stock Blending (BSB) System: Published papers describing the project, drivers, concept and economic model Buffers are critical... read more

Why 100% visual inspection does not mean 100% defect detection

Buffer Stock Blending (BSB) System: Published papers describing the project, drivers, concept and economic model Buffers are critical... read more

How to bridge the data integration gap between sponsors and contract organizations

Buffer Stock Blending (BSB) System: Published papers describing the project, drivers, concept and economic model Buffers are critical... read more

Bringing BioPhorum’s unique perspective to continuous manufacturing in biologics

Buffer Stock Blending (BSB) System: Published papers describing the project, drivers, concept and economic model Buffers are critical... read more

Supply Chain to Patient has launched!

Buffer Stock Blending (BSB) System: Published papers describing the project, drivers, concept and economic model Buffers are critical... read more

Electronic data exchange – the foundation for an efficient, resilient inbound supply chain

Buffer Stock Blending (BSB) System: Published papers describing the project, drivers, concept and economic model Buffers are critical... read more

How are you improving your environmental sustainability performance?

Buffer Stock Blending (BSB) System: Published papers describing the project, drivers, concept and economic model Buffers are critical... read more

Adding value for analytical instrument partners

Buffer Stock Blending (BSB) System: Published papers describing the project, drivers, concept and economic model Buffers are critical... read more

Introducing MediPhorum

The medical technology (MedTech) industry is a critical and complex sector. As highlighted during the Covid-19 pandemic, the MedTech industry provides a wide array of products and technologies that are vital to the safe and effective provision of care to many. Also, as seen over recent years, there is often the requirement for flexibility in supply, rapid development, and the introduction of new products to keep pace with global public health demands.

Advanced Wound Care and Wound Management

Advanced wound care (AWC) is the medical treatment for wounds that have not healed properly using conventional wound care products such as gauze, bandages, plasters, and wadding.

AWC involves treating chronic or complex wounds using products that are not as easily obtained over the counter. AWC can be divided into three main categories: wound healing, infection prevention, and restoration.

Drug Delivery

Drug delivery products are therapeutic and diagnostic products combining drugs, devices, and/or biological products, which enable safer and more efficient treatment due to careful and precise drug targeting, local administration, and tailored treatment.

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more
BioPhorum Deliverables Report
BioPhorum brings you the latest Deliverables Report, an informative and inspiring consolidation of the benchmarks, position papers, guidance documents, assessment tools, industry user requirements, study results, and roadmaps produced in the last twelve months.
BioPhorum Downloads
Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.
Case Studies
Welcome to the BioPhorum case studies page, where you can learn how our clients have used our service to discover innovative solutions and save money. Here you can read real-life stories of how various organizations have used our unique data-driven approach to streamline their processes and make the most of their resources. Whether you're looking for inspiration or want to learn more about the potential benefits of our service, you'll find it here.
Webinars and podcasts
Welcome to BioPhorum Connect, the podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, this podcast brings you the insights and perspectives of experts from around the world. We'll discuss all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. So, join us on our journey as we explore the world of biopharmaceuticals and learn from the perspectives of those at the forefront of the industry.